Sarepta Therapeutics (SRPT) Stock Research

Friday

Unusually active option classes on open August 7th

Aug 7, 9:40 AM

Thursday

Sarepta price target lowered by $2 at Oppenheimer, here's why

SRPT

Aug 6, 8:21 AM

Wednesday

Sarepta reports Q2 adjusted EPS 64c, consensus 49c

SRPT

Aug 5, 4:59 PM

Over a week ago

Morgan Stanley says Sarepta's CEO transition brings clarity ahead of catalysts

SRPT

Jul 27, 10:45 AM

Sarepta appoints Severino as Chief Executive Officer

SRPT

Jul 27, 8:32 AM

Citi sees intensifying competition for Sarepta from Dyne Therapeutics

Jul 21, 6:25 AM

Tractor Supply downgrade, Five Below upgraded: Wall Street's top analyst calls

+14

Jul 9, 9:47 AM

Sarepta price target lowered by $3 at Piper Sandler, here's why

SRPT

Jul 9, 7:14 AM

Sarepta just upgraded at Wolfe Research, here's why

SRPT

Jul 8, 5:07 PM

H.C. Wainwright says Sarepta news does not signal full approvals

SRPT

Jul 1, 6:18 AM

Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53

SRPT

Jun 30, 8:32 AM

Acting FDA head vows to block political interference, Endpoint News says

+23

Jun 4, 2:11 PM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

Sarepta price target lowered by $1 at Evercore ISI

SRPT

May 15, 8:25 AM

What You Missed On Wall Street On Tuesday

+47

May 12, 4:11 PM

FDA Commissioner Marty Makary resigns

+17

May 12, 1:58 PM

Trump Trade: Trump to suspend tariff-rate quotas on beef imports

+33

May 12, 10:47 AM

Trump approves plan to fire FDA head Marty Makary, CBS reports

+13

May 11, 12:22 PM

Trump Trade: U.S. plans AI security order without required model tests

+17

May 11, 10:09 AM

What You Missed On Wall Street On Friday

+37

May 8, 4:21 PM

Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year

SRPT

May 6, 5:11 PM

Private Markets: Cursor in talks for $2B, Blue Energy secures $380M

+25

Apr 23, 1:12 PM

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

Apr 16, 12:19 PM

Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says

+13

Apr 13, 3:33 PM

Sarepta price target raised by $1 at RBC Capital, here's why

SRPT

Apr 7, 9:37 AM

Pioneering Gene Therapy Market Entry for DMD: Sarepta has secured the first FDA approval for a gene therapy (ELEVIDYS) targeting Duchenne muscular dystrophy (DMD), establishing a significant first-mover advantage and a leading position in this high-need therapeutic area.

Established Exon-Skipping Franchise: With multiple FDA-approved exon-skipping therapies for DMD, Sarepta possesses a strong foundation of commercialized products and deep expertise in RNA-targeted treatments for neuromuscular diseases.

Robust Rare Disease Pipeline: Beyond its existing commercial products, Sarepta maintains a diverse and promising pipeline of gene therapies and RNA-based treatments for various forms of muscular dystrophies, indicating future growth potential.

Clinical Trial Outcomes: Failure of ongoing or future clinical trials to meet primary endpoints or demonstration of unacceptable adverse events could prevent or delay product approvals.

Regulatory Approval Hurdles: Delays, rejections, or stringent post-marketing requirements from regulatory bodies like the FDA for new drug applications or label expansions pose significant risks to commercialization.

Competitive Landscape: Development of superior, more effective, or more cost-efficient treatments by competitors for Duchenne Muscular Dystrophy and other rare diseases could erode market share.

Charts